Role of IL‐10 and IL‐22 cytokines in patients with primary immune thrombocytopenia and their clinical significance

BACKGROUND: Immune thrombocytopenia purpura (ITP) is an autoimmune disease that leads to accelerated platelet clearance. The objective of this study was to examine the clinical role of cytokines in ITP patients and to correlate them with disease stages. MATERIALS AND METHODS: A total of 110 ITP patients were enrolled, including 55 with active ITP, 55 with remission ITP, and 55 with healthy controls. The enzyme‐linked immunosorbent assay technique was used to examine IL‐10 and IL‐22 serum levels in all subjects. Real‐time quantitative PCR was used to assess the mRNA expression of IL‐10 and IL‐22 in PBMC. The clinical significance of both cytokines was assessed using ROC analysis. RESULTS: IL‐10 serum levels in active ITP patients were significantly lower than in control and remission ITP subjects (p < 0.05). IL‐22 serum levels were elevated in active ITP patients compared to the control and remission group (p < 0.05). mRNA expressions of IL‐10 and IL‐22 in active ITP patients were also having a significant difference from than control and remission ITP group (p < 0.05). ROC analysis showed that IL‐10 and IL‐22 can differentiate the ITP patients from controls. A positive correlation between serum IL‐10 and PBMC IL‐10 with statistical significance was observed. Similarly, the serum IL‐22 and PBMC IL‐22 were correlated positively with statistical significance. CONCLUSION: IL‐10 and IL‐22 seem to predict the clinical course of ITP, as a significant imbalance of these cytokines was detected in active ITP patients.